Upacicalcet

Drug profile

Key facts

Upacicalcet is a drug catalogued in DrugCentral. It was first approved by the PMDA in 2021. DrugCentral lists 1 molecular target, including CASR. Recorded indications include Secondary hyperparathyroidism.

• Molecular targets: CASR (1 listed in DrugCentral).
• Indications: Secondary hyperparathyroidism.
• Molecular formula: C11H14ClN3O6S; molecular weight 351.77 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Secondary hyperparathyroidism

Mechanism & targets

Molecular targets (1)

Target	Gene	Action	Activity
Extracellular calcium-sensing receptor	CASR	allosteric modulator	IC50 8.09

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2021-06-23	PMDA	—	SANWA KAGAKU KENKYUSHO Co., Ltd.

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Upacicalcet is on its molecule page.

• Molecular formula: C₁₁H₁₄ClN₃O₆S
• Molecular weight: 351.77 g/mol
• CAS number: —
• InChIKey: LHEYGVSDVBEYQF-QMMMGPOBSA-N
• PubChem CID: 53374467

CC1=C(C=C(C=C1Cl)S(=O)(=O)O)NC(=O)NC[C@@H](C(=O)O)N

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Upacicalcet used for?

DrugCentral lists the following indications for Upacicalcet: Secondary hyperparathyroidism.

How does Upacicalcet work?

Its molecular targets in DrugCentral include CASR (allosteric modulator).

When was Upacicalcet first approved?

Upacicalcet was first approved by the PMDA in 2021.

What is the chemical formula of Upacicalcet?

Upacicalcet has the molecular formula C11H14ClN3O6S and a molecular weight of 351.77 g/mol.

Sources

• DrugCentral drug card 5482 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL6068421 — compound record and bioactivity
• PubChem CID 53374467 — chemical identifiers
• FDA UNII 5C1222PBE2 — substance identity
• UniProt P41180 (CASR) — target protein

How this page is built: methodology · editorial policy & corrections.